clinical trial – Page 186 – Communicable Diseases Research

Repurposing Approved Drugs for Guiding COVID-19 Prophylaxis: A Systematic Review

Systematic Review

Published on 2020-12-142022-10-31
Journal: Frontiers in Pharmacology [Category] COVID-19,

Efficacy of commercial mouth-rinses on SARS-CoV-2 viral load in saliva: randomized control trial in Singapore

Controlled Trial

Published on 2020-12-142023-06-16
Journal: Infection [Category] MERS, SARS,

[키워드] antiseptics clinical trial COVID-19 Mouth-rinses Saliva SARS-CoV-2
[DOI] 10.1007/s15010-020-01563-9 PMC 바로가기 [Article Type] Controlled Trial

Human soluble ACE2 improves the effect of remdesivir in SARS‐CoV‐2 infection

인간 가용성 ACE2는 SARS-CoV-2 감염에서 렘데시비르의 효과를 향상시킵니다

Report

Published on 2020-12-142022-09-11
Journal: EMBO Molecular Medicine [Category] SARS, 치료제,

[키워드] ACE2 additive effect additive effects adenylate kinase antiviral drug antiviral drugs approach authorization Cell cell entry cell surface receptor cells clinical trial clinical trials combination therapy combination treatment concentrations COVID‐19 COVID‐19 Critical decrease dose Effect effective drug Efficiency highlighting HIV treatment Human human kidney IMPROVE infections investigated kidney kidney organoids kinase life life cycle Microbiology, Virology & Host Pathogen Interaction Mortality open outcome pathway provided receptor ACE2 reduce regimen Remdesivir Replication required Safe SARS‐CoV‐2 SARS‐CoV‐2 infection shown singular soluble ACE2 surface receptor targets therapeutic therapeutic window Toxicity Treatment Vero E6 Viral Viral load Viral RNA was used
[DOI] 10.15252/emmm.202013426 PMC 바로가기 [Article Type] Report

Biochemical and antigenic characterization of the structural proteins and their post-translational modifications in purified SARS-CoV-2 virions of an inactivated vaccine candidate

Original Article

Published on 2020-12-142022-10-31
Journal: Emerging Microbes & Infections [Category] COVID-19, SARS,

[키워드] Analysis anti-SARS-CoV-2 vaccines Antibody Response antibody response against antigenic antigenicity Antisera caused cleavage cleaved clinical trial convalescent convalescent serum COVID-19 pandemic demonstrated elicit facilitate FIVE form forms full-length S glycoprotein glycosylated immunization immunized immunogenic inactivated Inactivated vaccine membrane Modification modifications natural infection Neutralizing antibodies pathogenesis of SARS-CoV-2 post-translational modification protease Protein purified Quality control S glycoprotein S protein S1 and S2 S1/S2 subunit S2 subunit SARS-CoV-2 SARS-CoV-2 virion sera shown stimulated structural protein structural proteins subunit subunits the vaccine vaccination Vaccine vaccine candidate Vero virion virions
[DOI] 10.1080/22221751.2020.1855945 PMC 바로가기 [Article Type] Original Article

Challenges and Opportunities from Targeting Inflammatory Responses to SARS-CoV-2 Infection: A Narrative Review

Review

Published on 2020-12-122022-10-30
Journal: Journal of Clinical Medicine [Category] COVID-19,

[키워드] “cytokine storm” acute respiratory syndrome Anti-inflammatory anti-inflammatory drug Anti-inflammatory drugs anti-viral drug approach benefit Care challenge clinical care Clinical practice clinical trial clinician complementary condition Coronavirus-2 COVID-19 COVID-19 disease COVID-19 patient Cytokine storm develop disease severity drug early stage effective effective therapy effort Evidence expected global pandemic Host Hypothesis immune defense immunomodulation immunomodulatory activities Infection Inflammation Inflammatory introduced management morbidity and mortality narrative novel coronavirus disease opportunity patients pro-inflammatory cytokine Replication Research response review risk Safe SARS-CoV-2 SARS-CoV-2 entry severe cases Spread targeting the disease therapy Vaccines virus while worsening
[DOI] 10.3390/jcm9124021 PMC 바로가기 [Article Type] Review

Remote Methods for Conducting Tobacco-Focused Clinical Trials

담배 중심 임상 시험을 수행하기 위한 원격 방법

Review

Published on 2020-12-122022-09-11
Journal: Nicotine & tobacco research : official journal of [Category] SARS, 임상,

High-Dose Cholecalciferol Booster Therapy is Associated with a Reduced Risk of Mortality in Patients with COVID-19: A Cross-Sectional Multi-Centre Observational Study

고용량 콜레칼시페롤 부스터 요법은 COVID-19 환자의 사망률 감소와 관련이 있습니다: 횡단면 다중 센터 관찰 연구

Clinical Trial

Published on 2020-12-112022-08-13
Journal: Nutrients [Category] MERS, SARS, 임상,

[키워드] 2019 novel coronavirus 2019 novel coronavirus disease 25-hydroxyvitamin D 95% CI affected appear baseline carried cholecalciferol cholecalciferol booster therapy cholecalciferol therapy clinical trial Cohort collected confounder coronavirus disease COVID-19 COVID-19 mortality determine disease Efficacy hospitalised in-patient Logistic regression Mortality Novel coronavirus novel coronavirus 2019 novel coronavirus disease observational study participant Patient patients pharmacological management population studies predictor predictors public health recruited reduced risk replicated SARS-CoV-2 serum serum 25-hydroxyvitamin D therapeutic option therapeutic options Treatment UK hospitals validation cohort Vitamin D Vitamin D status vitamin D treatment was used with COVID-19 worldwide pandemic
[DOI] 10.3390/nu12123799 PMC 바로가기 [Article Type] Clinical Trial

Alpha-1 Antitrypsin for COVID-19 Treatment: Dual Role in Antiviral Infection and Anti-Inflammation

Perspective

Published on 2020-12-112022-10-31
Journal: Frontiers in Pharmacology [Category] COVID-19,

[키워드] Activation acute lung injury acute respiratory distress acute respiratory distress syndrome (ARDS) acute respiratory syndrome alpha-1 antitrypsin (A1AT) Anti-inflammation Anti-inflammatory anti-inflammatory drug Anti-inflammatory therapy antitrypsin Antiviral antiviral therapy approaches approved Blood cell death circulating clinical trial Coagulation coronavirus coronavirus disease 2019 (COVID- 19) COVID-19 COVID-19 disease COVID-19 patient deficiency demonstrated determine drug effective emphysema entry of SARS-CoV-2 glycoprotein host cells Human Infection Inflammation inhibit inhibiting involved moderate Neutrophil elastase Patient Prevent protease Protease inhibitor reducing role SARS-CoV-2 severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) severe lung injury syndrome therapy TMPRSS2 transmembrane serine protease treat Treatment unique
[DOI] 10.3389/fphar.2020.615398 PMC 바로가기 [Article Type] Perspective

Cloroquina y sus derivados en el manejo de la COVID-19: una revisión sistemática exploratoria

Artículo Original

Published on 2020-12-112022-10-28
Journal: Biomédica [Category] COVID-19, MERS, SARS,

[키워드] base China Chloroquine clinical trial cloroquina coronavirus COVID-19 ensayo clínico Hidroxicloroquina Hydroxychloroquine in vitro OMS Pandemia Pandemias Pandemics revisión sistemática SARS-CoV-2 systematic review virus
[DOI] 10.7705/biomedica.5478 PMC 바로가기 [Article Type] Artículo Original

SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments

SARS-CoV-2: 감염 및 백신 및 치료제 개발로 유발되는 면역 반응

Review

Published on 2020-12-112022-09-11
Journal: Frontiers in Immunology [Category] MERS, SARS, 진단, 치료기술, 치료제,

[키워드] acute respiratory syndrome coronavirus addition administration affected antiparasitic antivirals approach approved caused characterized clinical clinical evidence clinical manifestation clinical manifestations Clinical stages clinical trial clinical trials contribute convalescent serum coronavirus coronavirus 2 coronavirus disease COVID-19 COVID-19 disease current therapy deaths described development disease distress drug dry cough effective Evidence exacerbated FDA Fever food Food and Drug Administration headache Health Organization Human Hydroxychloroquine immune Immune cell immune cells immune response immunological imperative Infection Infectious disease information mediators Migration monoclonal antibody monoclonal antibody therapy neutralize organ pandemic Phase III clinical trials potential therapy Prevent proinflammatory mediator proinflammatory mediators respiratory respiratory distress response SARS-CoV-2 SARS-CoV-2 patients severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 Severe case severe cases Symptom tested therapy Treatment treatments Vaccine vaccine candidate Vaccines virus WHO World Health Organization
[DOI] 10.3389/fimmu.2020.569760 PMC 바로가기 [Article Type] Review